Mika Wallén1,2, Eija Tomás3, Tapio Visakorpi1,2, Kaija Holli4,5, Johanna Mäenpää6,7. 1. Institute of Medical Technology, University of Tampere, Tampere, Finland. 2. The Centre for Laboratory Medicine, Tampere University Hospital, Tampere, Finland. 3. Department of Obstetrics and Gynecology, Tampere University Hospital, 33521, Tampere, Finland. 4. Palliative Medicine, Tampere University Hospital, Tampere, Finland. 5. Medical School, University of Tampere, Tampere, Finland. 6. Department of Obstetrics and Gynecology, Tampere University Hospital, 33521, Tampere, Finland. johanna.maenpaa@pshp.fi. 7. Medical School, University of Tampere, Tampere, Finland. johanna.maenpaa@pshp.fi.
Abstract
PURPOSE: Long-term use of tamoxifen is associated with a two- to threefold increased risk of endometrial cancer in postmenopausal women. Toremifene is another triphenylethylene antiestrogen, which is as effective as tamoxifen in postmenopausal breast cancer. Thus far, its use has not been associated with an increased risk of endometrial cancer. K-ras codon 12 mutations seem to be important in endometrial carcinogenesis, and these mutations have been found in endometrial samples of patients on tamoxifen. The present study was undertaken to investigate if there is any difference in the frequency of endometrial K-ras mutations among patients treated with tamoxifen or toremifene. METHODS: Endometrial samples were taken from 23 postmenopausal breast cancer patients (tamoxifen, n = 11; toremifene, n = 12) before and after 36 months of treatment. DNA was isolated from formalin-fixed paraffin-embedded samples using a routine proteinase K digestion protocol. K-ras mutations in codon 12 were screened using real-time PCR and melting curve analysis in LightCycler equipment. Wild-type PNA oligomer was used to increase the sensitivity of the assay. RESULTS: All baseline samples contained wild-type K-ras, while 10/23 (43%) of the follow-up samples carried a codon 12 mutation. Mutations were identified in 3 of the 11 in the tamoxifen group and in 7 of the 12 in the toremifene group. Seven were transitions (G-->A), and three were transversions (two G-->T, one G-->C). One of the mutations in the toremifene group was associated with a polypoid endometrium. All the other mutations were found in an atrophic (n = 6) or proliferative (n = 3) endometrium. CONCLUSIONS: Both tamoxifen and toremifene induce endometrial K-ras codon 12 mutations. The significance of this finding to endometrial carcinogenesis remains to be elucidated.
PURPOSE: Long-term use of tamoxifen is associated with a two- to threefold increased risk of endometrial cancer in postmenopausal women. Toremifene is another triphenylethylene antiestrogen, which is as effective as tamoxifen in postmenopausal breast cancer. Thus far, its use has not been associated with an increased risk of endometrial cancer. K-ras codon 12 mutations seem to be important in endometrial carcinogenesis, and these mutations have been found in endometrial samples of patients on tamoxifen. The present study was undertaken to investigate if there is any difference in the frequency of endometrial K-ras mutations among patients treated with tamoxifen or toremifene. METHODS: Endometrial samples were taken from 23 postmenopausal breast cancerpatients (tamoxifen, n = 11; toremifene, n = 12) before and after 36 months of treatment. DNA was isolated from formalin-fixed paraffin-embedded samples using a routine proteinase K digestion protocol. K-ras mutations in codon 12 were screened using real-time PCR and melting curve analysis in LightCycler equipment. Wild-type PNA oligomer was used to increase the sensitivity of the assay. RESULTS: All baseline samples contained wild-type K-ras, while 10/23 (43%) of the follow-up samples carried a codon 12 mutation. Mutations were identified in 3 of the 11 in the tamoxifen group and in 7 of the 12 in the toremifene group. Seven were transitions (G-->A), and three were transversions (two G-->T, one G-->C). One of the mutations in the toremifene group was associated with a polypoid endometrium. All the other mutations were found in an atrophic (n = 6) or proliferative (n = 3) endometrium. CONCLUSIONS: Both tamoxifen and toremifene induce endometrial K-ras codon 12 mutations. The significance of this finding to endometrial carcinogenesis remains to be elucidated.
Authors: Guoli Chen; Matthew Theodore Olson; Alan O'Neill; Alexis Norris; Katie Beierl; Shuko Harada; Marija Debeljak; Keila Rivera-Roman; Samantha Finley; Amanda Stafford; Christopher David Gocke; Ming-Tseh Lin; James Richard Eshleman Journal: J Mol Diagn Date: 2012-02-10 Impact factor: 5.568
Authors: Oscar Fuster; Eva Barragán; Pascual Bolufer; José Cervera; Maria José Larráyoz; Antonio Jiménez-Velasco; Joaquín Martínez-López; Ana Valencia; Federico Moscardó; Miguel Angel Sanz Journal: J Mol Diagn Date: 2009-07-30 Impact factor: 5.568
Authors: Yohann Loriot; Pierre Mordant; Eric Deutsch; Ken André Olaussen; Jean-Charles Soria Journal: Nat Rev Clin Oncol Date: 2009-07-14 Impact factor: 66.675
Authors: Laura J Schild-Hay; Tarek A Leil; Rao L Divi; Ofelia A Olivero; Ainsley Weston; Miriam C Poirier Journal: Cancer Res Date: 2009-01-20 Impact factor: 12.701
Authors: E Nagy; K B Gajjar; I I Patel; S Taylor; P L Martin-Hirsch; H F Stringfellow; F L Martin; D H Phillips Journal: Br J Cancer Date: 2014-05-22 Impact factor: 7.640
Authors: Monika M Żyła; Jacek R Wilczyński; Marta Kostrzewa; Kinga Księżakowska-Łakoma; Marek Nowak; Grzegorz Stachowiak; Krzysztof Szyłło; Tomasz Stetkiewicz Journal: Prz Menopauzalny Date: 2016-11-15